VRCA241220C2500
- 0.05
- 0.000.00%
Verrica Pharmaceuticals Newsroom
Verrica Pharmaceuticals Appoints New Chief Operating Officer
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Verrica Pharmaceuticals' Partner Torii Seeks Japan Approval for Skin Infection Treatment
Express News | Verrica Pharmaceuticals Announces That Development Partner Torii Pharmaceutical Files New Drug Application of to-208 the Treatment of Molluscum Contagiosum in Japan
Verrica Pharmaceuticals Announces That Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan
Express News | Verrica Pharmaceuticals Inc - Offering Includes Series a and B Warrants for 23.6 Mln Shares Each
Verrica Announces Pricing of $42.0 Million Public Offering
Press Release: Verrica Announces Proposed Public Offering
Express News | Verrica Announces Proposed Public Offering
This Super Micro Computer Analyst Turns Bearish; Here Are Top 5 Upgrades For Wednesday
H.C. Wainwright Downgrades Verrica Pharmaceuticals(VRCA.US) to Hold Rating
Verrica Downgraded to Sector Perform by RBC Capital
Verrica Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Financial Results, Announced Senior Leadership Changes, and Is Exploring Strategies to Strengthen Its Balance Sheet. Additionally, RBC Capital...
Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings
TD Cowen Maintains Verrica Pharmaceuticals(VRCA.US) With Buy Rating, Cuts Target Price to $5
Verrica Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Verrica Pharmaceuticals Cut to Sector Perform From Outperform by RBC Capital
Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September
Needham Maintains Verrica Pharmaceuticals(VRCA.US) With Hold Rating